Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.53 |
| ▸ | ITGB6 | P18564 | 18/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237151 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL2232143 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL2232146 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21745032 | 0.88 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL22631925 | 0.88 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL327992 | 0.88 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL327985 | 0.88 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL328144 | 0.88 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL8268188 | 0.88 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL328036 | 0.88 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2021-07-01 | — | — | US | disclosed |
| EP-3613739-B1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-11-04 | — | — | EP | disclosed |
| US-10703752-B2 | Integrin antagonists | Oxurion NV (BE) | 2020-07-07 | — | — | US | disclosed |
| EP-3613739-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-26 | — | — | EP | disclosed |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | ITGAV 5/4885ITGB6 16/4885ITGB3 10/4885 |
| US-10703752-B2 | Integrin antagonists | ITGB1, ITGA2B, ITGA1 | ITGAV 5/4885ITGB6 17/4885ITGB3 11/4885 |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | ITGAV 5/4885ITGB6 17/4885ITGB3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.